Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of alzheimer’s disease

Current Topics in Medicinal Chemistry

Volumn 16, Issue 5, 2016, Pages 565-573

  Xiao, Rong ^a  

^a LIAONING NORMAL UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Cognition deficits; Epileptic seizures; Levetiracetam

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ETIRACETAM; PLACEBO; PIRACETAM;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXPERIMENTAL BEHAVIORAL TEST; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOMA; HIPPOCAMPUS; HUMAN; INTRACTABLE EPILEPSY; LOW DRUG DOSE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NONHUMAN; QUALITY OF LIFE; SCORING SYSTEM; SEIZURE; SPATIAL MEMORY; TEMPORAL LOBE EPILEPSY; TRANSGENIC MOUSE; VERBAL MEMORY; WISCONSIN CARD SORTING TEST; ANALOGS AND DERIVATIVES; ANIMAL; COGNITION DISORDERS; COMPLICATION;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; HUMANS; PIRACETAM;

EID: 84973427498     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150813144603     Document Type: Article

References (86)

1. Smith, C. M.; Swash, M. Possible biochemical basis of memory disorder in Alzheimer disease. Ann. Neurol., 1978, 3(6), 471-473.
2. Joray, S.; Herrmann, F.; Mulligan, R.; Schnider, A. Mechanism of disorientation in Alzheimer’s disease. Eur. Neurol., 2004, 52(4), 193-197.
3. Schecker, M.; Kochler, C.; Schmidtke, K.; Rauh, R. Are there any connections between language deficits and cognitive slowing in Alzheimer’s disease? Dement. Geriatr. Cogn. Dis. Extra, 2014, 4(3), 442-449.
4. Ogawa, N.; Hosomi, J.; Koura, S.; Oshikawa, T.; Tateishi, N.; Tanaka, M.; Kamijyo, K.; Tanigawa, Y. Intervention for several behavioural disorders in Alzheimer’s-type dementia. Psychogeriatrics, 2012, 12(2), 133-136.
5. Jia, J. P.; Wang, F.; Yuan, Q.; Qin, W.; Tang, Y.; Zuo, X. M.; Han, Y. Progresses on genetics of predementia phase of Alzheimer’s disease. Prog. Biochem. Biophys., 2012, 39(8), 698-702.
6. Kuo, Y. M.; Emmerling, M. R.; Woods, A. S.; Cotter, R. J.; Roher, A. E. Isolation, chemical characterization, and quantitation of Aβ3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem. Biophys. Res. Commun., 1997, 237(1), 188-191.
7. Lu, J.; Li, T.; He, R. Q.; Bartlett, P. F.; Götz, J. Visualizing the microtubule-associated protein tau in the nucleus. Sci. China Life Sci., 2014, 57(4), 422-431.
8. Lu, J.; Miao, J. Y.; Su, T.; Liu, Y.; He, R. Q. Formaldehyde induces hyperphosphorylation and polymerization of Tau protein both in vitro and in vivo. Biochim. Biophys. Acta., 2013, 1830(8), 4102-4116.
9. Price, D. L.; Whitehouse, P. J.; Struble, R. G. Alzheimer’s disease. Annu. Rev. Med., 1985, 36, 349-356.
10. Palop, J. J.; Mucke, L. Amyloid-β induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat. Neurosci., 2010, 13(7), 812-818.
11. Tseng, B. P.; Kitazawa, M.; LaFerla, F. M. Amyloid β peptide: the inside story. Curr. Alzheimer Res., 2004, 1(4), 231-239.
12. Jiang, T. Brainnetome and related projects. Sci. China Life Sci., 2014, 57(4), 462-466.
13. Santos, S. F.; Pierrot, N.; Octave, J. N. Network excitability dysfunction in Alzheimer’s disease: insights from in vitro and in vivo models. Rev. Neurosci., 2010, 21(3), 153-171.
14. Nguyen, T. H.; Qiu, X. F.; Sun, J. Y.; Meunier, F. A. Bulk endocytosis at neuronal synapses. Sci. China Life Sci., 2014, 57(4), 378-383.
15. Taylor, C. J.; He, R. Q.; Bartlett, P. F. The role of the N-methyl-Daspartate receptor in the proliferation of adult hippocampal neural stem and precursor cells. Sci. China Life Sci., 2014, 57(4), 403-411.
16. Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L.; Goebel, W. D.; James, M. J.; Brunden, K. R.; Wilson, D. A.; Landreth, G. E. ApoEdirected therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science, 2012, 335(6075), 1503-1506.
17. Zhou, H.; Mangelsdorf, M.; Liu, J. H.; Zhu, L.; Wu, J. Y. RNAbinding proteins in neurological diseases. Sci. China Life Sci., 2014, 57(4), 432-444.
18. Chen, J. Y.; Sun, M. R.; Wang, X. H.; Lu, J.; Wei, Y.; Tan, Y.; Liu, Y.; Götz, J.; He, R. Q.; Hua, Q. The herbal compound geniposide rescues formaldehyde-induced apoptosis in N2a neuroblastoma cells. Sci. China Life Sci., 2014, 57(4), 412-421.
19. Su, T.; Xin, L.; He, Y. G.; Wei, Y.; Song, Y. X.; Li, W. W.; Wang, X. M.; He, R. Q. The abnormally high level of uric D-ribose for type 2 diabetics. Prog. Biochem. Biophys., 2013, 40(9), 816-825.
20. Su, T.; He, R. Q. D-ribose, an overlooked player in type 2 diabetes mellitus? Sci. China Life Sci., 2014, 57(3), 361.
21. Kumar, A.; Ekavali, A. S.; A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol. Rep., 2015, 67(2), 195-203.
22. Amatniek, J. C.; Hauser, W. A.; DelCastillo-Castaneda, C.; Jacobs, D. M.; Marder, K.; Bell, K.; Albert, M.; Brandt, J.; Stern, Y. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia, 2006, 47(5), 867-872.
23. Palop, J. J.; Mucke, L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol., 2009, 66(4), 435-440.
24. Friedman, D.; Honig, L. S.; Scarmeas, N. Seizures and epilepsy in Alzheimer’s disease. CNS. Neurosci. Ther., 2012, 18(4), 285-294.
25. Imfeld, P.; Bodmer, M.; Schuerch, M.; Jick, S. S.; Meier, C. R. Seizures in patients with Alzheimer’s disease or vascular dementia: a population-based nested case-control analysis. Epilepsia, 2013, 54(4), 700-707.
26. Sherzai, D.; Losey, T.; Vega, S.; Sherzai, A. Seizures and dementia in the elderly: nationwide inpatient sample 1999-2008. Epilepsy Behav., 2014, 36, 53-56.
27. Chan, J.; Jones, N. C.; Bush, A. I.; O’Brien, T. J.; Kwan, P. A mouse model of Alzheimer’s disease displays increased susceptibility to kindling and seizure-associated death. Epilepsia, 2015, 56(6), e73-77.
28. Li, B. Y.; Chen, S. D. Potential similarities in temporal lobe epilepsy and Alzheimer’s disease: from clinic to pathology. Am. J. Alzheimers Dis. Other Demen., 2014, 1-6.
29. de Krom, M. Cognitive dysfunction in epilepsy: case reports. Seizure, 2006, 15(4), 264-266.
30. Dulay, M. F.; York, M. K.; Soety, E. M.; Hamilton, W. J.; Mizrahi, E. M.; Goldsmith, I. L.; Verma, A.; Grossman, R. G.; Yoshor, D.; Armstrong, D. D.; Levin, H. S. Memory, emotional and vocational impairments before and after anterior temporal lobectomy for complex partial seizures. Epilepsia, 2006, 47(11), 1922-1930.
31. Vossel, K. A.; Beagle, A. J.; Rabinovici, G. D.; Shu, H.; Lee, S. E.; Naasan, G.; Hegde, M.; Cornes, S. B.; Henry, M. L.; Nelson, A. B.; Seeley, W. W.; Geschwind, M. D.; Gorno-Tempini, M. L.; Shih, T.; Kirsch, H. E.; Garcia, P. A.; Miller, B. L.; Mucke, L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA. Neurol., 2013, 70(9), 1158-1166.
32. Ijff, D. M.; Aldenkamp, A. P. Cognitive side-effects of antiepileptic drugs in children. Handb. Clin. Neurol., 2013, 111, 707-718.
33. Wright, C.; Downing, J.; Mungall, D.; Khan, O.; Williams, A.; Fonkem, E.; Garrett, D.; Aceves, J.; Kirmani, B. Clinical pharmacology and pharmacokinetics of levetiracetam. Front. Neurol., 2013, 4, 192.
34. Kim, J. S.; Lee, J. H.; Ryu, H. W.; Lim, B. C.; Hwang, H.; Chae, J. H.; Choi, J.; Kim, K. J.; Hwang, Y. S.; Kim, H. Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus. Pediatr. Emerg. Care, 2014, 30(8), 525-528.
35. Fonkem, E.; Bricker, P.; Mungall, D.; Aceves, J.; Ebwe, E.; Tang, W.; Kirmani, B. The role of levetiracetam in treatment of seizures in brain tumor patients. Front. Neurol., 2013, 4, 153.
36. Werhahn, K. J.; Klimpe, S.; Balkaya, S.; Trinka, E.; Krämer, G. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure, 2011, 20(4), 305-311.
37. Helmstaedter, C.; Witt, J. A. Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial. Epilepsy Behav., 2010, 18(1-2), 74-80.
38. Piazzini, A.; Chifari, R.; Canevini, M. P.; Turner, K.; Fontana, S. P.; Canger, R. Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res., 2006, 68(3), 181-188.
39. Cheng, G.; Whitehead, S. N.; Hachinski, V.; Cechetto, D. F. Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiol. Dis., 2006, 23(1), 140-151.
40. Abd-El-Fattah, M. A.; Abdelakader, N. F.; Zaki, H. F. Pyrrolidine dithiocarbamate protects against scopolamine-induced cognitive impairment in rats. Eur. J. Pharmacol., 2014, 723, 330-338.
41. Zhang, J.; Jiang, W.; Zuo, Z. Pyrrolidine dithiocarbamate attenuates surgery-induced neuroinflammation and cognitive dysfunction possibly via inhibition of nuclear factor κB. Neuroscience, 2014, 261, 1-10.
42. Wang, Z.; Zhao, H.; Peng, S.; Zuo, Z. Intranasal pyrrolidine dithiocarbamate decreases brain inflammatory mediators and provides neuroprotection after brain hypoxia-ischemia in neonatal rats. Exp. Neurol., 2013, 249, 74-82.
43. Zhou, B.; Zhang, Q.; Tian, L.; Xiao, J.; Stefan, H.; Zhou, D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav., 2008, 12(2), 305-310.
44. Huang, C. W.; Pai, M. C.; Tsai, J. J. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry Clin. Neurosci., 2008, 62(5), 548-553.
45. López-Góngora, M.; Martínez-Domeño, A.; García, C.; Escartín, A. Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study. Epileptic Disord., 2008, 10(4), 297-305.
46. Belcastro, V.; Costa, C.; Galletti, F.; Pisani, F.; Calabresi, P.; Parnetti, L. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur. J. Neurol., 2007, 14(10), 1176-1178.
47. Cumbo, E.; Ligori, L. D. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav., 2010, 17(4), 461-466.
48. Englot, D. J.; Berger, M. S.; Chang, E. F.; Garcia, P. A. Characteristics and treatment of seizures in patients with highgrade glioma: a review. Neurosurg. Clin. N. Am., 2012, 23(2), 227-235.
49. de Groot, M.; Douw, L.; Sizoo, E. M.; Bosma, I.; Froklage, F. E.; Heimans, J. J.; Postma, T. J.; Klein, M.; Reijneveld, J. C. Levetiracetam improves verbal memory in high-grade glioma patients. Neuro. Oncol., 2013, 15(2), 216-223.
50. Putcha, D.; Brickhouse, M.; O’Keefe, K.; Sullivan, C.; Rentz, D.; Marshall, G.; Dickerson, B.; Sperling, R. Hippocampal hyperactivation associated with cortical thinning in Alzheimer’s disease signature regions in non-demented elderly adults. J. Neurosci., 2011, 31(48), 17680-17688.
51. Bakker, A.; Krauss, G. L.; Albert, M. S.; Speck, C. L.; Jones, L. R.; Stark, C. E.; Yassa, M. A.; Bassett, S. S.; Shelton, A. L.; Gallagher, M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron, 2012, 74(3), 467-474.
52. Yassa, M. A.; Stark, S. M.; Bakker, A.; Albert, M. S.; Gallagher, M.; Stark, C. E. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. Neuroimage, 2010, 51(3), 1242-1252.
53. Bakker, A.; Albert, M. S.; Krauss, G.; Speck, C. L.; Gallagher, M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin., 2015, 7, 688-698.
54. Margineanu, D. G.; Klitgaard, H. Levetiracetam has no significant γ-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. Eur. J. Pharmacol., 2003, 466(3), 255-261.
55. Sanchez, P. E.; Zhu, L.; Verret, L.; Vossel, K. A.; Orr, A. G.; Cirrito, J. R.; Devidze, N.; Ho, K.; Yu, G. Q.; Palop, J. J.; Mucke, L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc. Natl. Acad. Sci. USA, 2012, 109(42), E2895-2903.
56. Janz, R.; Goda, Y.; Geppert, M.; Missler, M.; Südhof, T. C. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron, 1999, 24(4), 1003-1016.
57. Lynch, B. A.; Lambeng, N.; Nocka, K.; Kensel-Hammes, P.; Bajjalieh, S. M.; Matagne, A.; Fuks, B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA, 2004, 101(26), 9861-9866.
58. Sugata, S.; Hanaya, R.; Kumafuji, K.; Tokudome, M.; Serikawa, T.; Kurisu, K.; Arita, K.; Sasa, M. Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneously epileptic rats. Brain Res. Bull., 2011, 86(1-2), 36-41.
59. Stettner, M.; Dehmel, T.; Mausberg, A. K.; Köhne, A.; Rose, C. R.; Kieseier, B. C. Levetiracetam exhibits protective properties on rat Schwann cells in vitro. J. Peripher. Nerv. Syst., 2011, 16(3), 250-260.
60. Shannon, H. E.; Love, P. L. Effects of antiepileptic drugs on working memory as assessed by spatial alternation performance in rats. Epilepsy Behav., 2004, 5(6), 857-865.
61. Lamberty, Y.; Margineanu, D. G.; Klitgaard, H. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy Behav., 2000, 1(5), 333-342.
62. Koh, M. T.; Haberman, R. P.; Foti, S.; McCown, T. J.; Gallagher, M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology, 2010, 35(4), 1016-1025.
63. Ozyurek, H.; Bozkurt, A.; Bilge, S.; Ciftcioglu, E.; Ilkaya, F.; Bas, D. B. Effect of prenatal levetiracetam exposure on motor and cognitive functions of rat offspring. Brain Dev., 2010, 32(5), 396-403.
64. Celikyurt, I. K.; Ulak, G.; Mutlu, O.; Akar, F. Y.; Mulayim, S.; Erden, F.; Komsuoglu, S. S. Positive impact of levetiracetam on emotional learning and memory in naive mice. Life Sci., 2012, 90(5-6), 185-189.
65. Devi, L.; Ohno, M. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer’s disease in mice. Neurobiol. Learn. Mem., 2013, 102, 7-11.
66. López-Toledano, M. A.; Shelanski, M. L. Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind). J. Alzheimers Dis., 2007, 12(3), 229-240.
67. Wright, A. L.; Zinn, R.; Hohensinn, B.; Konen, L. M.; Beynon, S. B.; Tan, R. P.; Clark, I. A.; Abdipranoto, A.; Vissel, B. Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One, 2013, 8(4), e59586.
68. Harris, J. A.; Devidze, N.; Halabisky, B.; Lo, I.; Thwin, M. T.; Yu, G. Q.; Bredesen, D. E.; Masliah, E.; Mucke, L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer’s disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci., 2010, 30(1), 372-381.
69. Meilandt, W. J.; Yu, G. Q.; Chin, J.; Roberson, E. D.; Palop, J. J.; Wu, T.; Scearce-Levie, K.; Mucke, L. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer’s disease. J. Neurosci., 2008, 28(19), 5007-5017.
70. Verret, L.; Mann, E. O.; Hang, G. B.; Barth, A. M.; Cobos, I.; Ho, K.; Devidze, N.; Masliah, E.; Kreitzer, A. C.; Mody, I.; Mucke, L.; Palop, J. J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell, 2012, 149(3), 708-721.
71. Hall, A. M.; Throesch, B. T.; Buckingham, S. C.; Markwardt, S. J.; Peng, Y.; Wang, Q.; Hoffman, D. A.; Roberson, E. D. Taudependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer’s disease. J. Neurosci., 2015, 35(15), 6221-6230.
72. Laursen, B.; Mørk, A.; Plath, N.; Kristiansen, U.; Bastlund, J. F. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice. Behav. Brain Res., 2013, 240, 146-152.
73. Xiong, H.; Callaghan, D.; Wodzinska, J.; Xu, J.; Premyslova, M.; Liu, Q. Y.; Connelly, J.; Zhang, W. Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer’s disease. Neurosci. Bull., 2011, 27(4), 221-232.
74. Zhang, W.; Hao, J.; Liu, R.; Zhang, Z.; Lei, G.; Su, C.; Miao, J.; Li, Z. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer’s disease. Behav. Brain Res., 2011, 222(2), 342-350.
75. Ruan, L.; Kang, Z.; Pei, G.; Le, Y. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer’s disease. Curr. Alzheimer Res., 2009, 6(6), 531-540.
76. Taniuchi, N.; Niidome, T.; Goto, Y.; Akaike, A.; Kihara, T.; Sugimoto, H. Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. Neuroreport, 2007, 18(17), 1801-1805.
77. Shi, J. Q.; Wang, B. R.; Tian, Y. Y.; Xu, J.; Gao, L.; Zhao, S. L.; Jiang, T.; Xie, H. G.; Zhang, Y. D. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS. Neurosci. Ther., 2013, 19(11), 871-881.
78. Zhang, L.; Liu, C.; Wu, J.; Tao, J. J.; Sui, X. L.; Yao, Z. G.; Xu, Y. F.; Huang, L.; Zhu, H.; Sheng, S. L.; Qin, C. Tubastatin A/ACY-1215 improves cognition in Alzheimer’s disease transgenic mice. J. Alzheimers Dis., 2014, 41(4), 1193-1205.
79. Ziemka-Nalecz, M.; Zalewska, T. Neuroprotective effects of histone deacetylase inhibitors in brain ischemia. Acta. Neurobiol. Exp., 2014, 74(4), 383-395.
80. Li, S.; Fossati, G.; Marchetti, C.; Modena, D.; Pozzi, P.; Reznikov, L. L.; Moras, M. L.; Azam, T.; Abbate, A.; Mascagni, P.; Dinarello, C. A. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J. Biol. Chem., 2015, 290(4), 2368-2378.
81. Hasan, M. R.; Kim, J. H.; Kim, Y. J.; Kwon, K. J.; Shin, C. Y.; Kim, H. Y.; Han, S. H.; Choi, D. H.; Lee, J. Effect of HDAC inhibitors on neuroprotection and neurite outgrowth in primary rat cortical neurons following ischemic insult. Neurochem. Res., 2013, 38(9), 1921-1934.
82. Eimer, W. A.; Vassar, R. Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation. Mol. Neurodegener., 2013, 8, 2.
83. Maarouf, C. L.; Kokjohn, T. A.; Whiteside, C. M.; Macias, M. P.; Kalback, W. M.; Sabbagh, M. N.; Beach, T. G.; Vassar, R.; Roher, A. E. Molecular differences and similarities between Alzheimer’s disease and the 5XFAD transgenic mouse model of amyloidosis. Biochem. Insights, 2013, 6, 1-10.
84. Oakley, H.; Cole, S. L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-Bongaarts, A.; Ohno, M.; Disterhoft, J.; Van Eldik, L.; Berry, R.; Vassar, R. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci., 2006, 26(40), 10129-10140.
85. Kimura, R.; Ohno, M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis., 2009, 33(2), 229-235.
86. Ohno, M. Failures to reconsolidate memory in a mouse model of Alzheimer’s disease. Neurobiol. Learn. Mem., 2009, 92(3), 455-459.